Eclevar MedTech is built on a rare combination of private investment from MedTech specialists and public recognition from the European clinical research community.
Platinum Award 2026
Top prize in the xShare x European CRO Federation "EHDS & Clinical Research" Open Call, awarded to Eclevar MedTech and its Milo Health platform, presented at the EUCROF 2026 conference in Amsterdam.
Horizon Europe · Grant Agreement No. 101136734 · Amsterdam, 2 Feb 2026
Eclevar MedTech is backed by Ballas Invest, an investment firm whose MedTech and digital-health portfolio includes leaders such as Wandercraft ($75M Series D) and Hexoskin. Its commitment is rooted in the development of MILO, our AI-driven clinical trial platform, recognised as a disruptive solution for medical device clinical research.
"ECLEVAR is at the forefront of clinical trial innovation. With Milo, the company has provided a groundbreaking solution that transforms the way trials are conducted."
Watch the video
On 2 February 2026 in Amsterdam, Eclevar MedTech received the Platinum Award, ranking first among European CROs evaluated by the European CRO Federation (EUCROF) in partnership with the European Commission.
Recognised for methodological rigour aligned with EU MDR.
Validation of the MILO architecture and its native regulatory-ecosystem compatibility.
Focus on inclusive, geographically diverse and sustainable clinical investigations.
Backed by a specialist MedTech investor with a long-term portfolio approach, Eclevar is structured for sustainable operations rather than short-cycle pressure.
When a Notified Body sees Eclevar on a clinical evaluation report, they see a CRO officially endorsed by EUCROF.
For investor relations, partnership enquiries or a closer look at the MILO clinical platform, we would be glad to speak with you.
Book a call